1. Introduction
===============

Systemic lupus erythematosus (SLE) is a prototypic, heterogeneous autoimmune disorder characterized by the presence of pathogenic autoantibodies which can affect multiple organs and systems.^\[[@R1]\]^ Although the underlying mechanism of SLE remains uncertain,^\[[@R2]\]^ genetic factors seem rather effective at its occurrence. Recent Genome-Wide Association studies (GWAS) revealed that some of single nucleotide polymorphisms (SNPs) in *GTF2I* gene were related to multiple autoimmune diseases,^\[[@R3]--[@R5]\]^ including primary Sjögren syndrome (pSS), rheumatoid arthritis, and SLE. However, as 1 of main clinical challenges of SLE, the genetic background of lupus nephritis (LN) has not been completely clarified. LN occurs in 15% - 55% of SLE patients, and patients from Asia have a higher prevalence than others and always present with a more severe disease.^\[[@R6]\]^ Whether *GTF2I* polymorphisms are associated with clinical indexes and disease manifestations among SLE patients is still uncertain, so we performed this case-control study on polymorphism rs117026326 and rs73366469, and explored the correlation of these locus to susceptibility to SLE and renal involvement in the present study.

2. Materials and methods
========================

2.1. Patients
-------------

This study was approved by the Ethics Committee of West China Hospital, having gained the ethic approval. Total of 800 individual participates including 400 SLE cases and 400 age- and gender-matched healthy controls (HC) were recruited from the West China Hospital. Informed consents for using their results were obtained from all the study participants and any form of registration that may identify a patient were excluded from the content of the paper.

All the SLE patients in the study were hospitalized patients, fulfilling the American College of Rheumatology 1997 classification criteria. Patients with drug-induced SLE were excluded.

Total of 400 healthy individuals randomly selected from the Health Examination Center were enrolled as HC. Their physical examinations and blood tests were all within normal range. None of these healthy individuals had infectious diseases, autoimmune disorders or family history of autoimmune diseases.

2.2. Clinical and laboratory evaluation
---------------------------------------

The clinical and laboratory data of the patients including proteinuria, rash, pericarditis, pleuritis, arthritis, the serum level of anti-dsDNA, anti-Sm, anti-RNP, IL-1β, IL-4, IL-6, urea, creatinine, CYS-C, uric acid, 24 hours UTP (g/24 hours) and 24-hour urinary protein level (g/L·24 hour) were recorded. Anti-dsDNA, anti-Sm, and anti-RNP were detected in all the 400 SLE patients. Anti-dsDNA was determined through indirect immunofluorescence, while anti-Sm and anti-RNP were estimated through line immunoassays (Euroimmun, Germany). 143 of SLE patients were selected randomly for cytokine testing. IL-1β, IL-4 and IL-6 were quantitatively detected using R&D Human Inflammation Assays.

All these tests were performed strictly in accordance with the relevant guidelines and regulations. Blood samples for assessing these indexes were detected at the same time.

2.3. GTF2I polymorphisms genotyping and linkage disequilibrium evaluation
-------------------------------------------------------------------------

All the samples were genotyped for rs117026326 and rs73366469 using improved multiplex ligation detection reaction (iMLDR) (Genesky Biotechnologies Inc, China). Polymerase chain reaction was performed at 95°C for 2 minutes followed by 11 cycles of denaturation (94°C, 20 seconds), annealing (65°C--0.5°C/cycle 40 seconds) and 24 cycles of 94°C 20 seconds, 59°C 30 seconds, 72°C 1 minutes 30 seconds, plus 1 cycle of 72°C for 2 minutes. During detection, some of samples were randomly selected for direct sequencing to confirm the results genotyped using iMLDR. The Haploview software version 4.2 was applied to perform linkage disequilibrium (LD) evaluation for combination of SNPs by calculating the pairwise *r*^2^ coeffcient.

2.4. Statistical analysis
-------------------------

Hardy--Weinberg equilibrium (HWE) was performed for the polymorphisms by the 2-sided Chi-Squared (*χ*^2^) test. Median and interquartile, mean ± SD or number and percentage were used to describe variables. Student *t* test or Mann--Whitney *U* test for quantitative variables were used to compare demographic and clinical data between patients and controls as appropriate. Chi-Square (*χ*^2^) test or Fisher exact test were applied to analyze differences in allelic and genotypic frequencies. If allele x is the major allele of the SNP, y is the minor allele, recessive model is known as xx + xy vs yy, dominant model as xx vs xy + yy, co-dominant model as xx vs xy vs yy. The association between genetic polymorphisms and LN, proteinuria was evaluated using the logistic regression model, calculated odds ratios (ORs) and 95% confidence intervals (CIs).

The statistical analyses were applied by using the Statistical Package for the Social Sciences (SPSS) software (version 19.0). Statistical power was calculated using "Power and Sample Size Calculation" software. A two-sided *P* value less than .05 was considered as statistically significant.

3. Results
==========

3.1. The main characteristics of the study population
-----------------------------------------------------

The demographic and clinical characteristics of all the included subjects were illustrated in Table [1](#T1){ref-type="table"}. The age (*P* = .323) and sex (*P* = .128) of SLE patients and controls were adequately matched. The average age of SLE patients and healthy controls were 36.33 ± 12.99 and 37.21 ± 12.16 years old, and the gender ratio (Female/male) were 359/41 and 345/55, respectively. Among all the SLE patients, the median disease duration is 36 months, the average SLEDAI score is 15.51 ± 7.54 and the average level of IL-4, IL-6, C3, C4 in SLE patients were 12.67 ± 32.40 pg/ml, 13.17 ± 26.94 pg/ml, 0.51 ± 0.22 g/L, 0.11 ± 0.06 g/L, respectively (Table [1](#T1){ref-type="table"}).
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Demographic and clinical features of the study participants.

![](medi-98-e16716-g001)

3.2. Polymorphisms association with SLE susceptibility
------------------------------------------------------

Cohorts showed no significant deviation from HWE for genotyped SNPs (all *P* \> .05). When comparing allele frequency of rs117026326 and rs73366469 between SLE patients and HC, significant differences were indicated (both *P* \< .001, statistical power = 1.000) with rs117026326 *T* allele correlated to an increased risk of SLE and rs73366469 *T* allele correlated to a decreased risk of SLE (Table [2](#T2){ref-type="table"}). The odds ratio and 95% confidence interval ((OR) 95% CI) were 3.265 (2.452--4.348) and 0.420 (0.325--0.543), respectively. When comparing genotype frequency, we observed that *TT* and *CT* genotype at rs117026326 and rs73366469 were associated with SLE susceptibility (*TT* at rs117026326: OR (95% CI) = 10.190 (3.526--29.449); *CT* at rs117026326: OR (95%CI) = 3.172 (2.269--4.435); *TT* at rs73366469: OR (95%CI) = 0.147 (0.064--0.336); *CT* at rs73366469: OR (95%CI) = 0.312 (0.133--0.731), all *P* \< .05). These results were also supported by further disease model analysis (rs117026326: Dominant model: OR (95% CI) = 3.568 (2.581--4.932); Recessive model: OR (95% CI) = 7.452 (2.589--21.447); rs73366469: Dominant model: OR (95% CI) = 0.186 (0.081--0.423); Recessive model: OR (95% CI) = 0.407 (0.302--0.550), All *P* \< .001).
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Genotype and allele frequencies of SNPs within GTF2IRD1-GTF2I region in SLE patients and controls.
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3.3. Polymorphisms association with clinical characteristics of SLE patients
----------------------------------------------------------------------------

SLE is a heterogeneous autoimmune disease. Patients with SLE always have variations in disease severity and clinical involvement. Thus, we tried to examine the effect of gene polymorphisms on clinical parameters and phenotypes among SLE patients, summarized in Table [3](#T3){ref-type="table"}. The results suggested that there was association between these polymorphisms and renal involvement in SLE patients.

###### 

Association between polymorphisms with clinical features in SLE patients.
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Although there was no significant association between the polymorphisms and levels of urea, creatinine, cystatin-C (CYS-C), uric acid, IL-4, IL-6, IL-1β in SLE patients, we found that the 24 hours UTP and 24-hour urinary protein level had significant difference in SLE patients with different genotypes of rs117026326 (*P* = .005, *P* = .030, respectively) or rs73366469 (*P* = .046, *P* = .002, respectively). SLE cases with CC genotype at rs117026326 had higher 24 hours UTP and 24-hour urinary protein level than patients with other genotypes, while cases with TT genotype at rs73366469 had significant increased 24 hours UTP and 24-hour urinary protein level than patients with other genotypes.

What\'s more, the frequency of proteinuria had significant difference in SLE patients with different genotypes of rs117026326 or rs73366469 (*χ*^2^ = 10.64, *P* \< .001; *χ*^2^ = 13.21, *P* = .001, respectively). When detailed analysis was performed on co-dominant model, results revealed that cases with TT genotype at rs117026326 (67.86%) had decreased frequency of the proteinuria than patients with CC genotype (89.38%) (*P* = .004), while cases with TT genotype at rs73366469 (90.00%) had significant increased frequency of the proteinuria than patients with CC genotype (68.57%) (*P* = .002). Furthermore, there was a strong trend towards significance when comparing the frequency of LN in patients with different genotypes of rs117026326 or rs73366469 (*P* = .051, .062, respectively). We also observed that the positive frequency of anti-dsDNA in patients with TT genotype at rs73366469 (82.73%) was significantly higher than those with CT genotype (72.41%) (*χ*^2^ = 5.532, *P* = .019).

Further analysis performed on recessive model indicted that patients with genotype TT at rs117026326 (42.85%) had significantly lower prevalence of LN than those with other genotypes (65.05%) (*P* = .019), while patients with genotype TT at rs73366469 (65.77%) had significantly higher prevalence of LN than patients with other genotypes (50.23%) (*P* = .001) (Table [4](#T4){ref-type="table"}).
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Association between polymorphisms with LN in SLE patients performed on recessive model.
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3.4. Linkage analysis
---------------------

We constructed the LD analysis of rs117026326 and rs73366469. The result showed that they were in strong linkage disequilibrium with *r*^2^ = 0.71 (Fig. [1](#F1){ref-type="fig"}).

![Linkage disequilibrium for rs117026326 and rs73366469 in *GTF2I* gene. The LD status is expounded by the *r*^2^ value. There was strong LD between two SNPs (*r*^2^ = 0.71).](medi-98-e16716-g005){#F1}

4. Discussion
=============

In this case-control study, we focused on the influence of *GTF2I* gene polymorphisms on susceptibility and clinical characteristics of SLE in a Chinese Han population. We described, for the first time, an interesting relationship between rs117026326, rs73366469 and kidney involvement of SLE patients. Results suggested that there was a highly significant association between rs117026326 and proteinuria, while rs73366469 was associated with proteinuria as well as expression of anti-dsDNA. Moreover, the association between two SNPs and the frequency of LN was also observed on recessive model.

*GTF2I* gene is clustered on chromosome 7 within a 1.8 Mb region. It can encode the transcription factor IIi (TFII-I) family, involving in regulation of growth factor signaling, immune cell signaling, and cell proliferation.^\[[@R7]\]^ As a signal-induced transcription, TFII-I can not only regulate transcription,^\[[@R8]\]^ signal transduction and development of bone, neural tissue,^\[[@R9]\]^ but also participate in the process of immune regulation. It can act as a cellular regulator of transcription from the promoter of cytomegalovirus, and its transcriptional regulation can be induced by immune signaling of lymphocytes. The activity of TFII-I is significantly related to expression of β-globin gene in erythroid cells.^\[[@R10]\]^ Previous study indicated that *GTF2I* gene can contribute to regulation of immunoglobulin heavy chain transcription in B lymphocytes.^\[[@R11]\]^ All these recent studies emphasized the validity and immune relevance of this gene.

Recent GWAS study identified susceptibility locus in GTF2I for pSS.^\[[@R5]\]^ Given the close clinical relationship and similar pathophysiological features between pSS and SLE, and given the fact that *GTF2I* gene is one of genetic susceptibility factors of SLE, *GTF2I* gene may play an essential role in SLE. rs117026326 is located in intron of *GTF2I* gene on chromosome 7q11.23 and was recently identified as a risk gene loci for pSS,^\[[@R12]\]^ RA^\[[@R13]\]^ and SLE.^\[[@R14],[@R15]\]^ rs73366469 is located within conserved enhancers, overlaps transcription start sites for *GTF2I* gene. It was also one of autoimmune susceptibility loci for RA^\[[@R13]\]^ and SLE.^\[[@R15]\]^ Our study indicated that rs117026326 and rs73366469 were candidate risk factors for SLE in a Chinese Han population, which further confirmed previously reported associations. What is more, differences exist in linkage disequilibrium in different populations. When only enrolling in West Chinese population, associations between rs73366469 and rs117026326 were consistently replicated, but the *r*^2^ in our study was higher than those in Kim and Sun, et al\'s study with Asian ancestry.^\[[@R13],[@R15]\]^

Although there was no correlation between rs117026326 genotypes and GTF2I expression,^\[[@R13]\]^ our study showed that the GTF2I polymorphisms are correlative with clinical parameters and phenotypes of SLE. As one of the most known devastating kidney-threatening manifestation of SLE patients,^\[[@R16],[@R17]\]^ LN affects about 40% to 70% of SLE patients and Asian, African populations have relatively higher incidence.^\[[@R18]\]^ Some genes have been shown to possess the potential of predisposing susceptible population to LN.^\[[@R19],[@R20]\]^ Proteinuria can indicate potential kidney disorders, suggestive for the presence of LN.^\[[@R21]\]^ With regard to autoimmune antibodies, anti-dsDNA as one of nephrotoxic autoantibodies can directly involve in renal pathology of SLE^\[[@R22],[@R23]\]^ and increased incidence of LN,^\[[@R24]\]^ of which one of the reasons is immune complex with anti-dsDNA can lead to renal inflammation if deposited in kidney,^\[[@R25]\]^ and may result in activation of complement, reactive oxygen species and some cytokines which are also causative factors of LN.^\[[@R26]\]^ Moreover, positive anti-Sm, anti-RNP^\[[@R27]--[@R29]\]^ and biomarkers for inflammation such as interleukin^\[[@R30]--[@R32]\]^ are also associated with renal involvement. Both IL-4 and IL-6 play important roles in kidney injury, IL-4 has function in polarization of macrophages to M2 phenotype, essential for recovery from acute kidney injury,^\[[@R33]\]^ while IL-6 is one of markers of chronic kidney damage. In addition, upregulation of IL-1β caused by TLR7 stimulation can lead to development of LN.^\[[@R34]\]^ In order to investigate relationship between GTF2I polymorphisms and kidney injury, we measured the frequency of proteinuria, LN, serum levels of clinical indexes which are related to kidney including urea, creatinine, CYS-C, uric acid, IL-4, IL-6, IL-1β and positivity of anti-dsDNA, anti-Sm, and anti-RNP. The result of our study showed that GTF2I polymorphisms were related to severity of kidney impairment of SLE.

Last year, an international group developed a new classification criteria for SLE patients. The criteria was based on a scoring system for clinical and laboratory domains. A positive antinuclear antibody (ANA) at a titer 1:80 or greater by immunofluorescence (IFA) is used as the entry criterion. The data in our study took years to collect, so we did not change the inclusion criteria in order to keep condition of enrolled patients in accordance with each other. All the SLE patients we enrolled have positive ANA, and the HC are from Health Examination Center of our hospital, so the diagnosis will not change by newer criteria and the result will hold true.

Ultimately, this is the first study carried out in Chinese SLE patients which is tempting to suppose that GTF2I polymorphisms were possibly useful predictors for kidney impairment in SLE patients. The present study suggested that 24 hours UTP, 24-hour urinary protein level, frequency of the proteinuria and prevalence of LN were significantly lower in cases with rs117026326 TT genotype, while patients with rs73366469 TT genotype had higher 24-hour urinary protein level, frequency of the proteinuria, prevalence of LN, and positive frequency of anti-dsDNA.
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